Get Newsletter
Alzheimer Research Forum - Networking for a Cure Alzheimer Research Forum - Networking for a CureAlzheimer Research Forum - Networking for a Cure
  
What's New HomeContact UsHow to CiteGet NewsletterBecome a MemberLogin          
Papers of the Week
Current Papers
ARF Recommends
Milestone Papers
Search All Papers
Search Comments
News
Research News
Drug News
Conference News
Research
AD Hypotheses
  AlzSWAN
  Current Hypotheses
  Hypothesis Factory
Forums
  Live Discussions
  Virtual Conferences
  Interviews
Enabling Technologies
  Workshops
  Research Tools
Compendia
  AlzGene
  AlzRisk
  Antibodies
  Biomarkers
  Mutations
  Protocols
  Research Models
  Video Gallery
Resources
  Bulletin Boards
  Conference Calendar
  Grants
  Jobs
Early-Onset Familial AD
Overview
Diagnosis/Genetics
Research
News
Profiles
Clinics
Drug Development
Companies
Tutorial
Drugs in Clinical Trials
Disease Management
About Alzheimer's
  FAQs
Diagnosis
  Clinical Guidelines
  Tests
  Brain Banks
Treatment
  Drugs and Therapies
Caregiving
  Patient Care
  Support Directory
  AD Experiences
Community
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
Mission
ARF Team
ARF Awards
Advisory Board
Sponsors
Partnerships
Fan Mail
Support Us
Return to Top
Home: Research: Forums: Virtual Conferences
1998 Society of Neuroscience Meeting - News


back to News


Alpha2-macroglobulin: a Novel Alzheimer's Disease Gene on Chromosome 12

Presented by Rudy Tanzi
Reported by Keith Crutcher

7 November 1998 AD is now widely considered to be a multifactorial disease with only a few dominant genetic mutations that can be considered as directly causing the disease, i.e., APP and the presenilins. The majority of genetic loci are likely to play broader, but less specific roles, in the disease and are commonly grouped together as "risk factors".

Dr. Tanzi reviewed the evidence from his group for a genetic association between AD and the gene encoding for alpha2-macroglobulin (A2M), a broad-spectrum protease inhibitor that is present in brain and plasma. The approach involved a family-based "sibship" analysis (exluding individuals younger than age 50 since they are more likely to represent familial forms associated with APP or the presenilins). The evidence strongly supports (p.00009) an increased incidence of a specific deletion affecting the A2M gene in affected siblings with no effect on age of onset. He noted that other groups had failed to find a similar linkage using "case-control" studies and suggested that this is probably due to the fact that identification of genes having subtle effects on disease risk are likely to be masked by population admixture. Family-based studies avoid this problem by effectively controlling for genetic background. He suggested that future studies will need to take this into consideration in order to unravel the complex nature of diseases for which many genes may contribute risk.




Desperately

Antibodies
Cell Lines
Collaborators
Papers
Research Participants
Copyright © 1996-2012 Alzheimer Research Forum Terms of Use How to Cite Privacy Policy Disclaimer Disclosure Copyright
wma logoadadad